Form 4 for CTSO Cytosorbents Corp

Accepted 2022-06-21 00:00:00 ET · period of report 2022-06-16 · accession 0001104659-22-072979 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-06-21	2022-06-16	CTSO	Chan Phillip P.	CEO, Dir	P - Purchase	$1.85	+2,221	768.4K	+0.3%	+$4,109

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-06-16	P	A	2,221	$1.85	768,351	D	—	—	(F4) (continued from footnote 3) (c) 528,351 shares of the Issuer's common stock owned by the reporting person, inclusive of the 2,221 shares of the Issuer's common stock reported on this Form 4. (F2) Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (F3) (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof; and